BACKGROUND AND PURPOSE: Intensity-modulated radiation therapy (IMRT) has proven extraordinary capability in physical terms such as target conformity, dose escalation in the target volume, and sparing of neighboring organs at risk. The radiobiological consequences of the protracted dose delivery for cell survival and cell cycle progression are still unclear and shall be examined in this study. MATERIAL AND METHODS: Human lymphoblasts (TK6) and human melanoma cells (MeWo) were irradiated with protocols of increasing dose protraction. In addition, a new biophysical phantom was developed and used to transfer clinical IMRT plans to experimental cell irradiation. Clonogenic cell survival and cell cycle analysis were performed after various irradiation experiments. RESULTS: In a first series of experiments, melanoma cells showed a highly significant increase of survival of 6.0% after protracted dose delivery of 2 Gy compared to conventional fast application with the same dose. Lymphoblastoid cells also showed a significant increase of survival of 2.2%. Experiments with patient plans in the phantom confirmed the trend of increased cell survival after protracted dose delivery. Cells were irradiated at 13 points in four different IMRT plans. In comparison to irradiation with application of the same dose in a classic four-field box, a significantly increased survival of 5.1% (mean value) was determined. CONCLUSION: Even at fraction times of 15-30 min the protracted dose delivery increases the survival rates in cell culture. The altered survival rates indicate the importance of the dose rate in the effectivity of IMRT. Besides physical parameters the consideration of biological factors might contribute to the optimization of IMRT in the future.
BACKGROUND AND PURPOSE: Intensity-modulated radiation therapy (IMRT) has proven extraordinary capability in physical terms such as target conformity, dose escalation in the target volume, and sparing of neighboring organs at risk. The radiobiological consequences of the protracted dose delivery for cell survival and cell cycle progression are still unclear and shall be examined in this study. MATERIAL AND METHODS:Human lymphoblasts (TK6) and humanmelanoma cells (MeWo) were irradiated with protocols of increasing dose protraction. In addition, a new biophysical phantom was developed and used to transfer clinical IMRT plans to experimental cell irradiation. Clonogenic cell survival and cell cycle analysis were performed after various irradiation experiments. RESULTS: In a first series of experiments, melanoma cells showed a highly significant increase of survival of 6.0% after protracted dose delivery of 2 Gy compared to conventional fast application with the same dose. Lymphoblastoid cells also showed a significant increase of survival of 2.2%. Experiments with patient plans in the phantom confirmed the trend of increased cell survival after protracted dose delivery. Cells were irradiated at 13 points in four different IMRT plans. In comparison to irradiation with application of the same dose in a classic four-field box, a significantly increased survival of 5.1% (mean value) was determined. CONCLUSION: Even at fraction times of 15-30 min the protracted dose delivery increases the survival rates in cell culture. The altered survival rates indicate the importance of the dose rate in the effectivity of IMRT. Besides physical parameters the consideration of biological factors might contribute to the optimization of IMRT in the future.
Authors: Florian Sterzing; Thomas B Brunner; Iris Ernst; Wolfgang W Baus; Burkhard Greve; Klaus Herfarth; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2014-08-05 Impact factor: 3.621
Authors: Frank Michael Klenke; Amir Abdollahi; Marc Bischof; Martha-Maria Gebhard; Volker Ewerbeck; Peter E Huber; Axel Sckell Journal: Strahlenther Onkol Date: 2010-12-23 Impact factor: 3.621
Authors: Felix Zwicker; Benedict Swartman; Falk Roeder; Florian Sterzing; Henrik Hauswald; Christian Thieke; Klaus-Josef Weber; Peter E Huber; Kai Schubert; Jürgen Debus; Klaus Herfarth Journal: J Radiat Res Date: 2014-10-31 Impact factor: 2.724
Authors: Stephanie E Combs; Wolfgang Behnisch; Andreas E Kulozik; Peter E Huber; Jürgen Debus; Daniela Schulz-Ertner Journal: BMC Cancer Date: 2007-09-13 Impact factor: 4.430
Authors: Sun Hyun Bae; Mi-Sook Kim; Won Il Jang; Chul Koo Cho; Hyung Jun Yoo; Kum Bae Kim; Chul Ju Han; Su Cheol Park; Dong Han Lee Journal: J Korean Med Sci Date: 2015-07-15 Impact factor: 2.153